CA-OPENGATE-CAPITAL
25.1.2019 09:02:10 CET | Business Wire | Press release
OpenGate Capital , a global private equity firm, announced today that its portfolio company, EverZinc, a European specialty zinc chemical business, has acquired G.H. Chemicals Ltd., and Microzinc Inc., collectively referred to as “GHC”, a Canadian manufacturer and exporter of French Process zinc oxide products. Terms of the transaction were not disclosed.
GHC was established in 1974 and is based in Saint Hyacinthe, Quebec. Through its manufacturing facility, GHC produces four grades of French Process zinc oxide used for pharmaceutical and food products, as well as fertilizer and feed grades, and various grades for rubber compounding. The business was acquired from Mr. Stephan Tabah and Mr. Philippe Bailet. GHC has a seasoned team of professionals and a highly trained employee base of 58 people serving a customer base of industrial, pharmaceutical and agriculture customers.
“The acquisition of GHC is a transformational investment for EverZinc that provides product and market expansion through world class facilities in Quebec,” said Andrew Nikou, OpenGate Capital’s Founder and CEO. “OpenGate’s strategy is to build both organic and inorganic growth for the businesses in which we invest. Earlier this year OpenGate launched OGx, a new digital optimization capability, to grow EverZinc and now GHC. Through the investment in GHC, and the OGx platform, we are confident that EverZinc’s global product offering will better serve its customers.”
Vincent Dujardin, CEO of EverZinc, stated, “We are excited to welcome GHC into the EverZinc portfolio and look forward to working together to leverage our respective products, processes and better serve our customer bases.”
Fabien Marcantetti, Managing Director in OpenGate’s Paris office, who led the transaction, added, “We are incredibly proud of completing this acquisition as the business provides many accretive aspects to EverZinc. Stephan and Philippe have driven advancements in the business and we are looking forward to working with them in the many months ahead.”
Julien Lagreze, Partner at OpenGate Capital, also commented, “The GHC transaction represents OpenGate’s second add-on acquisition which we believe further strengthens the investments acquired in our first institutional fund. I am very pleased that this is another milestone achieved within OpenGate’s investment strategy.”
OpenGate has completed two add-on investments including G.H. Chemicals and Aico S.P.A, an Italian manufacturer of home heating products, an add-on to Jøtul Group, acquired in March of 2018.
About OpenGate Capital
OpenGate Capital is a global private equity firm specializing in the acquisition and operation of businesses to create new value through operational improvements, innovation and growth. Established in 2005, OpenGate Capital is headquartered in Los Angeles, California with a European office in Paris, France. OpenGate’s professionals possess the critical skills needed to acquire, transition, operate, build and scale successful businesses. To date, OpenGate Capital, through its legacy and fund investments, has executed more than 30 acquisitions including corporate carve-outs, management buy-outs, special situations and transactions with private sellers across North America and Europe. To learn more about OpenGate, please visit www.opengatecapital.com .
About EverZinc
EverZinc is a global leader in the production of zinc materials with four product lines: fine zinc powders, zinc oxide, ultra-fine zinc powder and zinc powders for batteries. Industrial operations are in Belgium, the Netherlands, Norway, China and Malaysia. Close to 175,000 tons of materials are produced from 8 facilities to serve our global customer base. EverZinc products are used in a wide variety of applications including anti-corrosion paints, tires, pharma/chemicals, ceramics and glass, sunscreen, alkaline batteries and other products.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190125005009/en/
Contact:
OpenGate Media Contacts Alanna Chaffin Email: achaffin@opengatecapital.com Telephone: +1 (310) 432-7000
Mike Sitrick Sitrick & Company Email: Mike_Sitrick@sitrick.com Telephone: (310) 788-2850
OpenGate Business Development Contact Joshua Adams Email: jadams@opengatecapital.com Telephone: +1 (310) 432-7000
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Empire State Building Observation Deck to Debut ‘Olympus Awaits,’ An Immersive ‘Percy Jackson and the Olympians’ Takeover in the Heart of NYC, On Display from Nov. 16 – Dec. 4*12.11.2026 23:07:00 CET | Press release
The multi-level takeover includes a Throne Room, interactive photo opportunities, special lighting, and more The Empire State Building (ESB) is the gateway to Mount Olympus in Percy Jackson’s world, and now fans can experience the magic like never before. On Nov. 16, the Empire State Building Observation Deck (ESBOD) will unveil “Olympus Awaits,” a multi-level “Percy Jackson and the Olympians” takeover, in partnership with Disney+. The immersive takeover – included with every Observation Deck ticket – will feature an epic Throne Room, interactive photo opportunities, surprise giveaways, ESB x “Percy Jackson” merch, and more, available through Dec. 4, 2026.* This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112442266/en/ Empire State Building Observation Deck to Debut ‘Olympus Awaits,’ An Immersive ‘Percy Jackson and the Olympians’ Takeover in the Heart of NYC, On Display from Nov. 16 – Dec. 4* “This immersive NYC experience
Clene Nanomedicine Partners with Veristat to Reduce Biostatistical Output Time by 80% for ALS New Drug Application12.11.2026 18:09:00 CET | Press release
Veristat’s InStat™ delivers submission-ready tables, listings, and figures (TLFs) in one week using validated statistical engines, shortening the critical path from database lock to submission VeristatTM, a global clinical research organization (CRO) and consultancy specializing in complex studies, announced that it has partnered with Clene Nanomedicine to cut the time to deliver biostatistical outputs for a pivotal ALS drug application submission by 80%. Veristat reduced the time from study data to validated tables, listings and figures (TLFs) from up to six weeks to just one week. Clene, a late-stage biotech company, leveraged Veristat’s recently launched InStat™ platform, the industry’s first zero-code, fully automated solution to accelerate clinical trial processes. Biostatistical TLFs sit on the critical path for submissions, yet most sponsors rely on antiquated processes that involve slow, manual workflows to produce them, making post-database lock one of the biggest bottlenecks
WHOOP Launches WHOOP Humans, the Most Verifiably Human Social Network12.11.2026 18:00:00 CET | Press release
New feature lets members follow friends and family, share performance and health insights, and celebrate life's moments together WHOOP, the human performance brand, today launched WHOOP Humans, a new feature that lets members follow friends and family, share fitness, health, and performance data they choose, and support each other's progress. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112176779/en/ WHOOP Launches WHOOP Humans, the Most Verifiably Human Social Network For more than a decade, WHOOP has helped members better understand their own health and performance. Now, WHOOP Humans extends that experience beyond the individual, making it easier to celebrate achievements, encourage progress, and look out for the people who matter most. "In a world that's becoming increasingly artificial, we're building something deeply human,” said Will Ahmed, Founder and CEO of WHOOP. “This is the most verifiably human network ever
Integrated Hubs for Green Chemistry Research Aim to Transform How Chemicals and Materials Are Designed12.11.2026 17:00:00 CET | Press release
International network will investigate fundamental principles for creating safer, higher-performing chemicals and materials The Gordon and Betty Moore Foundation today announced four Integrated Research Hubs to explore new frontiers in chemical design, from materials that respond to their surroundings to molecules designed for safety from the start. Bringing together global researchers across institutions and disciplines, the hubs will investigate fundamental principles that could enable new capabilities in chemicals and materials while improving performance and protecting human health and the environment. The research priorities emerged through extensive engagement with the scientific community to identify the questions that could transform what chemistry can achieve. Each hub will connect researchers across institutions around one of four green chemistry focus areas: Safer molecular design: Led by The George Washington University, this hub will combine artificial intelligence and qua
Roquette Highlights Scalable Excipient and Capsule Solutions for Regional and Global Pharmaceutical Markets at CPHI India 202612.11.2026 16:00:00 CET | Press release
Helping pharmaceutical manufacturers accelerate the journey from formulation to market through deep technical expertise, meaningful innovation, close collaboration and global capabilities Roquette, a global leader in plant-based ingredients and a leading provider of pharmaceutical excipients, will showcase its comprehensive portfolio of excipient and capsule solutions at CPHI India 2026, Hall 1, Booth 1I12 from November 23 to 25, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112803410/en/ Meet Roquette at CPHI India 2026, Hall 1, Booth 1I12 At the event, Roquette will demonstrate how it helps pharmaceutical manufacturers accelerate the journey from formulation to market with confidence. By combining technical expertise, trusted quality, meaningful innovation and close collaboration, Roquette helps customers address formulation, scale-up and manufacturing challenges across a broad range of pharmaceutical application
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom